| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILA-C52H7 | Canine | Canine IL-17A / CTLA-8 Protein, His Tag |  |
|
|
| ILA-C5249 | Cynomolgus | Cynomolgus IL-17A / CTLA-8 Protein, His Tag |  |
|
|
| ILA-H82Q1 | Human | Biotinylated Human IL-17A / CTLA-8 Protein, His,Avitag™ |  |
|
|
| CT8-M5240 | Mouse | Mouse IL-17A / CTLA-8 Protein, His Tag (MALS verified) |  |
|
|
| ILA-H5118 | Human | Human IL-17A / CTLA-8 Protein, Tag Free (MALS verified) |  |
|
|
Mouse IL-17A, His Tag (Cat. No. CT8-M5240) stimulates secretion of IL-6 by NIH-3T3 cells. The ED50 for this effect is 2.132-5.005 ng/mL.
Loaded Biotinylated Human IL17A, His,Avitag (Cat. No. ILA-H82Q1) on SA Biosensor, can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with an affinity constant of 18.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Virulizin | Approved | Aptose | Virulizin, Virulizin-2 gamma | Mexico | Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | null | 1997-01-01 | Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Sarcoma, Kaposi; Melanoma; Uterine Cervical Neoplasms | Details | |
| Ixekizumab | LY-2439821 | Approved | Eli Lilly And Company | 拓咨, Taltz | EU | Spondylitis, Ankylosing | Eli Lilly Nederland Bv | 2016-03-22 | Non-radiographic axial spondyloarthritis; Spondylarthritis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic | Details |
| Secukinumab | AIN-457; KB-03303A; NVP-AIN-457 | Approved | Novartis Pharma Ag | 可善挺, Cosentyx | United States | Non-radiographic axial spondyloarthritis | Novartis Pharmaceuticals Corp | 2014-12-26 | Psoriasis; Crohn Disease; Plaque psoriasis; Gastroenteritis; Behcet Syndrome; Hidradenitis Suppurativa; Uveitis; Arthritis; Asthma; Parapsoriasis; Lichen Planus; Arthritis, Psoriatic; Tendinopathy; Non-radiographic axial spondyloarthritis; Graves Ophthalmopathy; Multiple Sclerosis; Arthritis, Juvenile; Lupus Nephritis; Arthritis, Rheumatoid; Spondylarthritis; Spondylitis, Ankylosing; Giant Cell Arteritis; Inflammatory Bowel Diseases; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| JNJ-63823539 | JNJ-63823539 | Phase 1 Clinical | Janssen Global Services Llc | Arthritis, Rheumatoid | Details |
| UCB-0159 | UCB-0159 | Phase 1 Clinical | Ucb Sa | Autoimmune Diseases | Details |
| COVA-322 | COVA-322 | Phase 2 Clinical | Covagen | Psoriasis | Details |
| ALX-0761 | M-1095; ALX-0761; MSB-0010841 | Phase 2 Clinical | Ablynx | Psoriasis | Details |
| Vidofludimus | 4SC-101; SC-12267 | Phase 2 Clinical | 4sc Ag | Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease | Details |
| ZL-1102 | ZL-1102 | Phase 1 Clinical | Zai Lab (Shanghai) Co Ltd | Psoriasis | Details |
| Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai Junshi Biosciences) | JS005 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Arthritis, Rheumatoid; Psoriasis; Plaque psoriasis | Details |
| QX002N | QX-002N | Phase 1 Clinical | Jiangsu Quanxin Biomedical Co Ltd | Spondylitis, Ankylosing | Details |
| Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai CP Guojian) | Phase 2 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Psoriasis; Plaque psoriasis | Details | |
| GR-1501 | GR-1501 | Phase 3 Clinical | Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd, Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd | Spondylarthritis; Psoriasis; Plaque psoriasis | Details |
| BAT-2306 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis | Details | |
| CJM-112 | CJM-112 | Phase 2 Clinical | Novartis Pharma Ag | Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Myeloma; Multiple Sclerosis; Psoriasis; Colorectal Neoplasms; Asthma; Hidradenitis Suppurativa; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) | LZM－012; LZM012 | Phase 2 Clinical | Livzon Pharmaceutical Group Inc, Beijing Xinkanghe Biomedical Technology Co Ltd | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| ABY-035 | AFB-035; ABY-035; IMG-020; IMG020 | Phase 2 Clinical | Affibody | Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Uveitis | Details |
| AK-111 | AK-111 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| Recombinant humanized anti-IL17A monoclonal antibody(Shanghai CP Guojian) | 608 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Psoriasis | Details |
| Vunakizumab | SHR-1314 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Spondylarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Lupus Nephritis; Psoriasis; Plaque psoriasis | Details |
This web search service is supported by Google Inc.
A-Z
